SEATTLE — A clinical study suggests that the Synchrony accommodating IOL from Visiogen is safe and stable in the eye, achieving an accommodative amplitude of more than 2.75 D at up to 18 months ...

IRVINE, Calif. — Enrollment has closed for a phase 3 study investigating the efficacy of Visiogen's Synchrony dual optic accommodating IOL, the company announced in a press release. The study is ...

Visiogen Inc., an Irvine-based eye device maker, has raised $16.5 million in venture capital financing. The new funding brings Visiogen’s total raised to at least $21.3 million in its two years of ...

The arena of premium IOLs is changing rapidly. The current choices in PC-IOLs include refractive multifocal IOLs, diffractive multifocal IOLs, and accommodating IOLs. A proper clinician understanding ...